Anti-CD20 Antibody is Effective in the Patient with Refractory Amegakaryocytic Thrombocytopenia, 25 Months Follow up
,
Abstract
Amegakaryocytic thrombocytopenia (AMT) is a rare cause of acquired thrombocytopenia. The pathogenesis and treatment of AMT is not clearly known. Here we demonstrate a 50-year-old man presented with the clinical manifestations of severe thrombocytopenia (7000 platelets/µl) with a marked decrease to absent of megakaryocytes in the bone marrow. The patient did not respond to intravenous immunoglobulin, cyclosporine or high dose prednisone. After the treatment with anti-CD20 antibody (Rituximab), the patient's clinical symptoms and platelet counts improved.
Manoharan A, Williams NT, Sparrow R. Acquired amegakaryocytic thrombocytopenia: report of a case and review of literature. Q J Med 1989;70:243-52.
Katsumata Y, Suzuki T, Kuwana M, et al. Anti-c-Mpl (thrombopoietin receptor) autoantibody-induced amegakaryocytic thrombocytopenia in a patient with systemic sclerosis. Arthritis Rheum 2003;48:1647-51.
Kuwana M, Okazaki Y, Kajihara M, et al. Autoantibody to c-Mpl (thrombopoietin receptor) in systemic lupus erythematosus: relationship to thrombocytopenia with megakaryocytic hypoplasia. Arthritis Rheum 2002;46:2148-59.
Shiozaki H, Miyawaki S, Kuwaki T, Hagiwara T, Kato T, Miyazaki H. Autoantibodies neutralizing thrombopoietin in a patient with amegakaryocytic thrombocytopenic purpura. Blood 2000;95:2187-8.
Benedetti F, de Sabata D, Perona G. T suppressor activated lymphocytes (CD8+/DR+) inhibit megakaryocyte progenitor cell differentiation in a case of acquired amegakaryocytic thrombocytopenic purpura. Stem Cells 1994;12:205-13.
Kuwana M, Kaburaki J, Okazaki Y, Miyazaki H, Ikeda Y. Two types of autoantibody-mediated thrombocytopenia in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2006;45:851-4. Epub 2006 Jan 17.
Lachowicz JL, Post GS, Moroff SD, Mooney SC. Acquired amegakaryocytic thrombocytopenia--four cases and a literature review. J Small Anim Pract 2004;45:507-14.
Banno F, Chauhan AK, Miyata T. The function of ADAMTS13 in thrombogenesis in vivo: insights from mutant mice. Int J Hematol 2010;91:30-5.
Tsai HM. Pathophysiology of thrombotic thrombocytopenic purpura. Int J Hematol 2010;91:1-19.
Lachowicz JL, Post GS, Moroff SD, Mooney SC. Acquired amegakaryocytic thrombocytopenia--four cases and a literature review. J Small Anim Pract 2004;45:507-14.
Smeets RE, Hillen HF. Acquired amegakaryocytic thrombocytopenic purpura. Treatment with high-dose dexamethasone pulse therapy and review of the literature. Neth J Med 1988;32:27-33.
Niparuck P, Atichartakarn V, Chuncharunee S. Successful treatment of acquired amegakaryocytic thrombocytopenic purpura refractory to corticosteroids and intravenous immunoglobulin with antithymocyte globulin and cyclosporin. Int J Hematol 2008;88:223-6.
El Omri H, Skouri H, Kraiem I, et al. [Acquired amegakaryocytic thrombocytopenic purpura treated with intravenous immunoglobulins]. Ann Med Interne (Paris) 2000;151:223-6.
elSaghir NS, Geltman RL. Treatment of acquired amegakaryocytic thrombocytopenic purpura with cyclophosphamide. Am J Med 1986;81:139-42.
Kashyap R, Choudhry VP, Pati HP. Danazol therapy in cyclic acquired amegakaryocytic thrombocytopenic purpura: a case report. Am J Hematol 1999;60:225-8.
Kayser W, Euler HH, Schmitz N, Gassmann W, Loffler H, Asbeck F. Danazol in acquired amegakaryocytic thrombocytopenic purpura: a case report. Blut 1985;51:401-4.
Lonial S, Bilodeau PA, Langston AA, et al. Acquired amegakaryocytic thrombocytopenia treated with allogeneic BMT: a case report and review of the literature. Bone Marrow Transplant 1999;24:1337-41.
Trimble MS, Glynn MF, Brain MC. Amegakaryocytic thrombocytopenia of 4 years duration: successful treatment with antithymocyte globulin. Am J Hematol 1991;37:126-7.
Her MY, Kim TH, Chang HK, Lee WS, Yoo DH. Successful treatment of acquired amegakaryocytic thrombocytopenia with cyclosporine in adult onset Still's disease. Rheumatol Int 2007;27:295-8. Epub 2006 Sep 7.
Leach JW, Hussein KK, George JN. Acquired pure megakaryocytic aplasia report of two cases with long-term responses to antithymocyte globulin and cyclosporine. Am J Hematol 1999;62:115-7.
Chaudhary UB, Eberwine SF, Hege KM. Acquired amegakaryocytic thrombocytopenia purpura and eosinophilic fasciitis: a long relapsing and remitting course. Am J Hematol 2004;75:146-50.
Agarwal N, Spahr JE, Werner TL, Newton DL, Rodgers GM. Acquired amegakaryocytic thrombocytopenic purpura. Am J Hematol 2006;81:132-5.
Fukushima T, Dong L, Sakai T, et al. Successful treatment of amegakaryocytic thrombocytopenia with anti-CD20 antibody (rituximab) in a patient with systemic lupus erythematosus. Lupus 2008;17:210-4.
Deeren D, Dorpe JV. Effective use of rituximab for acquired amegakaryocytic thrombocytopenia. Am J Hematol 2010;85:977-8.
Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90:2188-95.
Cela I, Miller IJ, Katz RS, Rizman A, Shammo JM. Successful treatment of amegakaryocytic thrombocytopenia with eltrombopag in a patient with systemic lupus erythematosus (SLE). Clin Adv Hematol Oncol 2010;8:806-9.
| Files | ||
| Issue | Vol 8, No 2 (2014) | |
| Section | Articles | |
| Keywords | ||
| Amegakaryocytic thrombocytopenia Anti-CD20 antibody Platelet | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
